EYSUVIS: Alcon to Acquire Eysuvis in a Move That Adds to Its Ophthalmic Eye Drop Portfolio

GENEVA-Alcon (SIX/NYSE: ALC) said on Monday that it has signed an agreement to acquire Eysuvis (loteprednol etabonate suspension) 0.25% pharmaceutical eye drops from Kala Pharmaceuticals Inc. The acquisition will complement Alcon's existing portfolio in the large and fast-growing dry eye category, according to the company's announcement. As part of the agreement, Alcon also will acquire Inveltys (loteprednol etabonate suspension) 1%, the only corticosteroid for twice-a-day treatment of post-operative inflammation and pain following ocular surgery, according to the announcement.